Method of effecting immunosuppression by administering carbocyclic adenosine analogs
AssigneeMerrell Pharmaceuticals Inc.
InventorsDavid R. Borcherding, Carl K. Edwards, III, Ronald E. Esser
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerrell Pharmaceuticals Inc.
InventorsDavid R. Borcherding, Carl K. Edwards, III, Ronald E. Esser
Estimating the term…
This invention relates to methods of effecting immunosuppression and inhibiting tumor necrosis factor .alpha. in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of a compound of the formula ##STR1## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent, Y.sub.3 is N, Y.sub.7, Y.sub.8 and Y.sub.9 are each independently nitrogen or a CH group, Q is NH.sub.2, halogen or hydrogen, and Z is hydrogen, halogen, or NH.sub.2 ; or a pharmaceutically-acceptable salt thereof. Also presented are pharmaceutical compositions comprising compounds of the same formula.
A method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of a compound of the formula ##STR7## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,
A method of inhibiting tumor necrosis factor .alpha. production in a patient in need thereof comprising administering to said patient an effective amount of a compound of the formula ##STR8## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,
A composition comprising a compound of the formula ##STR9## wherein the hydroxyl substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent
A pharmaceutical composition comprising an effective immunosuppressive amount of a compound of the formula ##STR10## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
In which the condensed system contains two hetero rings: ortho-condensed systems
Ortho- or peri-condensed with heterocyclic rings: purines, e.g. adenine
Heterocyclic compounds containing purine ring systems
In which the condensed system contains two hetero rings: ortho-condensed systems
Term ended 20 May 2014 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to certain carbocyclic adenosine analogs which are useful as immunosuppressants.
Immunity is concerned with the recognition and disposal of foreign antigenic material which is present in the body. Typically the antigens are in the form of particulate matter (i.e., cells, bacteria, etc.) or large protein or polysaccharide molecules which are recognized by the immune system as being "non-self", i.e., detectably different or foreign from the animals own constituents. Potential antigens can be a variety of substances, often proteins, which are most frequently located on the outer surfaces of cells. For example, potential antigens can be found on pollen grains, tissue grafts, animal parasites, viruses, and bacteria. Once the antigenic material is recognized as "non-self" by the immune system, natural (non-specific) and/or adaptive immune responses can be initiated and maintained by the action of specific immune cells, antibodies and the complement system. Under certain conditions, including in certain disease states, an animal's immune system will recognize its own constituents as "non-self" and initiate an immune response against "self" material.
An immune response can be carried out by the immune system by means of natural or adaptive mechanisms, each of which are composed of both cell-mediated and humoral elements. Natural mechanisms for immune response refer to those mechanisms involved in essentially non-specific immune reactions which involve the complement system and myeloid cells alone, such as macrophages, mast cells and polymorphonuclear leukocytes (PMN), in reacting to certain bacteria, viruses, tissue damage and other antigens. These natural mechanisms provide what is referred to as natural immunity. Adaptive mechanisms for immune response refer to those mechanisms which are mediated by lymphocytes (T and B cells) and antibodies which can respond selectively to thousands of different materials recognized as "non-self". These adaptive mechanisms provide what is referred to as adaptive immunity and lead to a specific memory and a permanently altered pattern of response in adaptation to the animal's own environment. Adaptive immunity can be provided by the lymphocytes and antibodies alone or, more commonly, can be provided by the interaction of lymphocytes and antibodies with the complement system and myeloid cells of the natural mechanisms of immunity. The antibodies provide the humoral element of the adaptive immune response and the T-cells provide the cell-mediated element of the adaptive immune response.
The following examples present a typical synthesis as described by Scheme A. These examples are understood to be illustrative only and is not intended to limit the scope of the invention in any way. As used herein, the following terms have the indicated meanings: "g" refers to grams; "mmol" refers to millimoles; "mL" refers to milliliters; "DMF" refers to dimethylformamide; ".degree.C." refers to degrees Celsius; "mg" refers to milligrams; "N" refers to the normality of a solution; "psi" refers to pounds per square inch; "THF" refers to tetrahydrofuran.
Step a: (1R,4S)-Cis-1-acetoxy-4-(2-tetrahydropyranyloxy)-2-cyclopentene
To a stirring solution of (1R,4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (1 g, 7.0 mmol) in 20 mL of dichloromethane add 3,4-dihydro-2H-pyran (0.6 g, 7.1 mmol) and 5 drops of trifluoroacetic acid. Stir the mixture for 24 hours. Dilute the mixture with 50 mL of dichloromethane and extract with saturated sodium bicarbonate and then brine. Dry the organic layer over sodium sulfate. Remove the solvent under vacuum to yield the title compound (1.58 g).